A Study of Disease Progression and Anti-HIV Treatments

Influence of Risk Status for Disease Progression on the Response to Antiretroviral Interventions: A Follow-up Study to ACTG 175

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00001068

Enrollment

210

Registered

2001-08-31

Start date

Unknown

Completion date

1998-10-31

Last updated

2021-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

Zalcitabine, Didanosine, Drug Therapy, Combination, AIDS-Related Complex, Antiviral Agents, Zidovudine, Lamivudine

Brief summary

To determine the influence of virus load, CD4 count, biologic phenotype, and presence of symptomatic disease on the response of HIV-infected patients to a new therapeutic regimen. PER AMENDMENT 8/27/96: To extend the availability of currently assigned ACTG 303 treatment for 6 months.

Interventions

DRUGLamivudine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Eligibility

Sex/Gender

ALL

Age

12 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients must have: * Prior participation on protocol ACTG 175. PER AMENDMENT 8/27/96: * Patients must be on study/on treatment at the time the protocol study treatment is extended.

Countries

Puerto Rico, Tanzania, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026